Christie M. Verkleij

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial.

Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology
Published: June 06, 2025

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels.

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels.

Journal: HemaSphere
Published: March 17, 2025

A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy.

A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy.

Journal: Blood
Published: January 27, 2025

Circulating extracellular vesicle isomiR signatures predict therapy response in patients with multiple myeloma.

Circulating extracellular vesicle isomiR signatures predict therapy response in patients with multiple myeloma.

Journal: Cell reports. Medicine
Published: December 03, 2024

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy.

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy.

Journal: Blood
Published: August 08, 2024

Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma.

Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma.

Journal: Journal for immunotherapy of cancer
Published: July 07, 2024

Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing.

Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing.

Journal: HemaSphere
Published: April 20, 2024

T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.

T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 30, 2023

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.

Journal: Blood advances
Published: September 11, 2023

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.

Journal: Current opinion in oncology
Published: July 28, 2023

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.

Journal: HemaSphere
Published: November 07, 2022

Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.

Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.

Journal: Cancer research communications
Published: February 16, 2022
Showing 1-12 of 22

Last Updated: 09/26/2026